Michael Nowicki

334 followers

San Francisco, California, United States

Connect with Michael Nowicki to Send Message

Connect

Connect with Michael Nowicki to Send Message

Connect

Timeline
About me
Director Medical Information at Genentech
Education
- Veterans Affairs Medical Center
  2008 - 2009
  ASHP-Accredited PGY1 Pharmacy Practice Residency Geriatrics Track
- University of Connecticut
  2002 - 2008
  Doctor of Pharmacy (PharmD) Pharmacy
  Activities and Societies: RHO CHI Pharmacy Honors Society
Experience
- Veterans Affairs Medical Center
  Aug 2009 - Apr 2011
  - Acute Care of Elders Clinical Pharmacist
    Jun 2010 - Apr 2011
  - Per Diem Staff Pharmacist
    Aug 2009 - Apr 2011
- Veterans Affairs Community Living Center
  Nov 2009 - Dec 2010
  Drug Regimen Review Pharmacist
- University of California, San Francisco
  Apr 2011 - Oct 2013
  Health Sciences Assistant Clinical Professor
- UCSF Medical Center
  Apr 2011 - Oct 2013
  Clinical Pharmacist, Adult General Surgery
- Genentech
  Oct 2013 - now
  - Director Medical Information Solid Tumor
    Aug 2020 - now
  - Senior Medical Science Director
    Apr 2018 - Aug 2020
  - Senior Medical Communications Leader
    Oct 2013 - Apr 2018
Licenses & Certifications
- Pharmacist
  California State Board of Pharmacy
  Dec 2008
- Pharmacist
  Connecticut Commission of Pharmacy
  Jun 2008
Honors & Awards
- Awarded to Michael Nowicki
  Above and Beyond Award Genentech 2017 Awarded by the Lung|GI Marketing team for contributions made on the Tecentriq Program Review Committee during the peri- and post-launch period for the first-line, cis-ineligible urothelial carcinoma launch.
- Awarded to Michael Nowicki
  Collaborative Brand Partner Genentech 2017 Recognizes an individual or team within Genentech outside of marketing that demonstrates exemplary collaboration with marketing, including flexibility, good communication, alignment with objectives and creative thinking.
- Awarded to Michael Nowicki
  Above and Beyond Award Genentech 2016 Awarded by the Lung|GI Marketing team for contributions made on the Tecentriq Program Review Committee during the peri- and post-launch period for the second-line urothelial carcinoma and non-small cell lung cancer launches.